Yat Sun Or,Jun Ma,Guoqiang Wang,Jiang Long,Bin Wang
申请号:
US15839249
公开号:
US20180162905A1
申请日:
2017.12.12
申请国别(地区):
US
年份:
2018
代理人:
摘要:
The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.